True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
Researchers have proposed using 3 externally validated nomograms to predict local, regional, and distant recurrence in patients with thin primary cutaneous melanomas.
The FDA has approved cemiplimab-rwlc, a PD-1 blocking antibody, for the treatment of patients with locally advanced basal cell carcinoma (laBCC) and has metastatic BCC (mBCC).
Study findings suggest that by including skin cancer content in cosmetology curricula, cosmetologists can be better screen their clients for suspicious lesions.
According to A. Hunter Shain, PhD, and colleagues, melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.
First-line pembrolizumab monotherapy is safe and effective for treating patients with unresectable CSCC, according to findings from a phase 2 study.
True or False: Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC patient, including durable complete and partial responses.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.